Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness AnalysisEdward Li, Gary H. Lyman, Kim Campbell et al.|JCO Oncology Practice|2021Cited by 19
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysisAli McBride, Weijia Wang, Bridgette Kanz Schroader et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 11
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, Bridgette Kanz Schroader et al.|Journal of health economics and outcomes research|2021Cited by 2
The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data AnalysisEdward Li, Weijia Wang, Kim Campbell et al.|Journal of health economics and outcomes research|2021Cited by 1